Related Experiment Video
Updated: Jun 20, 2026
12:24
Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
Published on: September 29, 2016
Intracellular signal pathways: potential for therapies
Melissa Mavers1, Eric M Ruderman, Harris Perlman
1Department of Medicine, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, McGaw Pavilion, Chicago, IL 60611, USA.
Current Rheumatology Reports
|September 24, 2009
Summary
Novel rheumatoid arthritis treatments targeting intracellular signal transduction molecules show promise. While p38 kinase inhibitors failed, Janus kinase and spleen tyrosine kinase inhibitors offer hope for improved therapies.
Area of Science:
- Rheumatology
- Pharmacology
- Molecular Biology
Background:
- Current rheumatoid arthritis therapies have limitations, including high costs and adverse events.
- Targeting intracellular signal transduction pathways is a novel therapeutic strategy for rheumatoid arthritis.
- Previous attempts using p38 kinase inhibitors showed limited success due to efficacy and safety concerns.
Purpose of the Study:
- To review the efficacy and safety of novel signal transduction inhibitors for rheumatoid arthritis.
- To evaluate the potential of targeting Janus kinases (JAK) and spleen tyrosine kinase (SYK) in rheumatoid arthritis treatment.
- To emphasize the importance of specificity analysis and transparent reporting of trial results.
Main Methods:
- Analysis of clinical trial data for signal transduction inhibitors in rheumatoid arthritis.
- Review of studies investigating p38 kinase, Janus kinase, and spleen tyrosine kinase inhibitors.
- Assessment of reported efficacy, adverse events, and specificity of targeted therapies.
Main Results:
- Janus kinase (JAK) and spleen tyrosine kinase (SYK) inhibitors have demonstrated greater success in clinical trials compared to p38 kinase inhibitors.
- Adverse events associated with p38 kinase inhibitors may be linked to off-target effects or mechanism-related events.
- Successful inhibition of signal transduction pathways offers a promising avenue for rheumatoid arthritis treatment.
Conclusions:
- Targeting specific signal transduction molecules like JAK and SYK represents a promising approach for rheumatoid arthritis.
- Continued rigorous analysis of drug specificity and transparent reporting of all trial outcomes are crucial.
- The success of these novel drugs offers optimism for developing more cost-effective and improved rheumatoid arthritis therapies.
Related Concept Videos
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:24Intracellular Signaling Cascades
Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...
01:24Intracellular Signaling Cascades
Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...
01:26Signal Transduction: Overview
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...
01:22Diversity in Cell Signaling Responses
The physiological function of a cell and cellular communication are outcomes of a range of extrinsic signals, intracellular signaling pathways, and cellular responses. No two cell types express the same repertoire of signaling components. Receptors are highly selective for their cognate ligands, but once activated, they can alter multiple cellular processes such as DNA transcription, protein synthesis, and metabolic activity.
Graded and Abrupt Responses
Some signaling systems generate...
Graded and Abrupt Responses
Some signaling systems generate...
01:15Amplifying Signals via Second Messengers
Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...